A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis

Trial Profile

A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs LY-3316531 (Primary) ; LY-3316531 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Sep 2018 Planned End Date changed from 1 Sep 2019 to 2 Sep 2019.
    • 12 Sep 2018 Planned primary completion date changed from 1 Feb 2019 to 12 Feb 2019.
    • 06 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top